Collectively, our results provide strong evidence for Cx32 centrally involved in the preferential uptake and propagation of oα-syn assemblies, pinpointing Cx32 as a novel therapeutic target to impede the uptake and spread of α-syn pathology in PD and related α-synucleinopathies. Here, GJB1 is linked to synucleinopathy.